Abstract: The invention relates to an ophthalmic pharmaceutical composition and its preparation methods and applications, wherein the pharmaceutical composition comprises of L-Alanyl-L-Glutamine suspended or dissolved in an isoosmotic solution suitable for human eyes, and has the advantages causing minimal irritation, with high stability and a good safety profile, and which can be used for relieving dry eye disease (DED) symptoms and/or improving and/or treating DED.

Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: An isobaric stable isotope-containing phosphorylated protein labeling reagent, and a preparation method and application thereof are provided. The protein labeling reagent is a phosphorylated dipeptide organophosphorus reagent labeled by a stable isotope such as deuterium-2, carbon-13, oxygen-18, or nitrogen-15. The preparation method includes: (1) preparation of an isobaric stable isotope-containing amino acid with N-terminal protection, (2) preparation of an isobaric stable isotope-containing amino acid activated ester Fmoc/Boc-R1-NHS with N-terminal protection, (3) preparation of an isobaric stable isotope-containing dipeptide, (4) preparation of an isobaric stable isotope-containing phosphite, (5) preparation of an isobaric stable isotope-containing phosphite dipeptide, and (6) preparation of a stable isotope-labeled N-phosphorylated amino acid activated ester.

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The invention relates to an ophthalmic pharmaceutical composition and its preparation methods and applications, wherein the pharmaceutical composition comprises of L-Alanyl-L-Glutamine suspended or dissolved in an isoosmotic solution suitable for human eyes, and has the advantages causing minimal irritation, with high stability and a good safety profile, and which can be used for relieving dry eye disease (DED) symptoms and/or improving and/or treating DED.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: An automatic high-speed rotary atomizing device, comprising a rotary spray head with an upper portion and a lower portion, the upper portion is connected to pressurized fluid, the lower portion is connected to the upper portion by means of one or more spray nozzles (1, 3) or spray orifices via a bearing (56). The upper portion is stationary. When the pressurized fluid is sprayed out from the spray nozzle, part of kinetic energy of the pressurized fluid generates a counterforce that propels the entire lower portion of the spray head to rotate at a high speed, so as to convert most of the kinetic energy of the pressurized fluid into surface energy that facilitates atomization of water flow when the pressurized fluid hits against a slanted surface or slit of the spray nozzle or passes through an aperture thereof, thereby forming a large-scale atomized, dispersed and swirling system.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: An automatic high-speed rotary atomizing device, comprising a rotary spray head with an upper portion and a lower portion, the upper portion is connected to pressurized fluid, the lower portion is connected to the upper portion by means of one or more spray nozzles (1, 3) or spray orifices via a bearing (56). The upper portion is stationary. When the pressurized fluid is sprayed out from the spray nozzle, part of kinetic energy of the pressurized fluid generates a counterforce that propels the entire lower portion of the spray head to rotate at a high speed, so as to convert most of the kinetic energy of the pressurized fluid into surface energy that facilitates atomization of water flow when the pressurized fluid hits against a slanted surface or slit of the spray nozzle or passes through an aperture thereof, thereby forming a large-scale atomized, dispersed and swirling system.

Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CH2F, —CH2CF2CH3, —CH2CH2CF3, —CH2CH(CH3)CF3, —CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or —CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.